Abstract
Approximately 50% of patients with aggressive non-Hodgkin's lymphomas (NHL) achieve a complete remission (CR) and cure with combination chemotherapy. The International Index is a useful clinical measure that predicts the patients' tolerance of therapy and likelihood of achieving CR, but it is not a direct measure of chemosensitivity. In this study we have investigated the predictive value of the tumor suppressor gene, p53, as a biological marker for response to treatment in the aggressive NHL. A retrospective study was carried out on 50 patients with aggressive NHL who were treated with CHOP chemotherapy. Treatment outcome was correlated with the expression of p53 in the lymphoma, as measured by routine immunohistochemistry using the monoclonal antibody Do-7. Forty percent of the lymphomas had >5% of the cells staining positively for p53 and this finding correlated significantly with response to treatment. Fifty percent of patients with p53 positive tumors achieved a CR versus 77% of patients with p53 negative tumors. In addition, the relapse rate and time to relapse were significantly different in the two groups. In the p53 positive group, 60% of patients relapsed in a median time of 6 months, whereas 26% of the p53 negative g...Continue Reading
References
Feb 1, 1975·Lancet·V T DeVitaR C Young
Oct 1, 1976·Annals of Internal Medicine·P S ScheinR C Young
Oct 1, 1976·Cancer·E M McKelveyT E Moon
Nov 5, 1992·The New England Journal of Medicine·L I GordonA Gottlieb
Sep 18, 1992·Cell·Y YinG M Wahl
Apr 8, 1993·The New England Journal of Medicine·R I FisherT P Miller
Dec 9, 1993·The New England Journal of Medicine·R M MeyerL E Shepherd
Apr 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F ChangK Syrjänen
Mar 1, 1995·Leukemia & Lymphoma·M A PirisP Martinez
Jan 1, 1995·Advances in Cancer Research·G Selivanova, K G Wiman
Jan 1, 1995·British Journal of Haematology·S KocialkowskiK C Gatter
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Sep 24, 1993·Cell·S W LoweD E Housman
Apr 8, 1993·The New England Journal of Medicine·J O Armitage
Apr 29, 1993·Nature·S W LoweT Jacks
Dec 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A ShippL N Shulman
Jan 1, 1996·Nature Medicine·A F WahlD A Galloway
Citations
Jul 11, 2001·Advances in Anatomic Pathology·E D Hsi, S Yegappan
Mar 17, 2006·Applied Immunohistochemistry & Molecular Morphology : AIMM·Paola ChabayMaria Victoria Preciado
Jun 19, 2004·Leukemia & Lymphoma·Lucia LoniRomano Danesi
Jan 21, 2003·Leukemia & Lymphoma·Rose-Marie AminiGunilla Enblad
Nov 8, 2001·Leukemia & Lymphoma·C Sarkodee-AdooT Heller
Jul 28, 2006·Journal of Pharmacological and Toxicological Methods·Behzad ForoutanDiana Anderson
Apr 21, 2006·Journal of Pharmacological and Toxicological Methods·Behzad ForoutanDiana Anderson
Jan 28, 2015·Journal of Translational Medicine·Chun-Nun ChaoChih-En Tseng
Jan 1, 2001·Hematology·A M Gruszka-Westwood
Jul 12, 2002·Proteomics·Anja MöllerEdmund Maser
Aug 3, 2002·Leukemia & Lymphoma·Rose-Marie AminiChrister Sundström
May 9, 2001·American Journal of Hematology·K B PagnanoS T Saad
Sep 6, 2000·Nature Medicine·C A SchmittS W Lowe
May 23, 2001·Blood·A M Gruszka-WestwoodD Catovsky
Aug 9, 2001·Blood·G Laurent, J P Jaffrézou
Jul 19, 2000·Journal of Neurochemistry·S Di BartolomeoA Spinedi
Aug 30, 2013·Experimental Biology and Medicine·Steve A Maxwell, Seyed Mousavi-Fard